n.a. (ANAC)

0.00
NASDAQ
Prev Close 0.00
Day Low/High 0.00 / 0.00
52 Wk Low/High 0.00 / 0.00
Exchange NASDAQ
Div & Yield N.A. (N.A)
Anacor Pharmaceuticals (ANAC) Stock Spiked on Positive Phase 3 Study Results

Anacor Pharmaceuticals (ANAC) Stock Spiked on Positive Phase 3 Study Results

Anacor Pharmaceuticals (ANAC) shares rose nearly 60% following the company's announcement of positive test results for its topical ointment treatment for eczema.

Market Wrap: Progress on Greek Deal Lifts Stocks

Natural gas pops and the VIX falls.

Stocks Celebrate Greek Debt Deal With Market Rally

Stocks Celebrate Greek Debt Deal With Market Rally

U.S. investors cheer an agreement between Greece and its European creditors following months of back-and-forth deliberations.

Stocks Hold Gains; Microsoft Shoots Higher

Stocks Hold Gains; Microsoft Shoots Higher

Stocks rally after Greece and its European creditors seal a debt deal.

Anacor Pharmaceuticals (ANAC) Trading With Heavy Volume Before Market Open

Anacor Pharmaceuticals (ANAC) Trading With Heavy Volume Before Market Open

Trade-Ideas LLC identified Anacor Pharmaceuticals (ANAC) as a pre-market mover with heavy volume candidate

Anacor Prescription Lotion Clears Skin Rash in Late-Stage Test

Anacor Prescription Lotion Clears Skin Rash in Late-Stage Test

Anacor intends to seek U.S. approval for a skin rash lotion, crisaborole, in the first half of next year, based on data collected from studies.

Anacor Pharmaceuticals Announces Positive Top-Line Results From Two Phase 3 Pivotal Studies Of Crisaborole Topical Ointment, 2% In Patients With Mild-to-Moderate Atopic Dermatitis

Anacor Pharmaceuticals Announces Positive Top-Line Results From Two Phase 3 Pivotal Studies Of Crisaborole Topical Ointment, 2% In Patients With Mild-to-Moderate Atopic Dermatitis

Anacor Pharmaceuticals, Inc. (NASDAQ:ANAC) today announced preliminary top-line results from its two Phase 3 pivotal studies of Crisaborole Topical Ointment, 2% (formerly AN2728), a novel non-steroidal topical...

New Lifetime High For Anacor Pharmaceuticals (ANAC)

New Lifetime High For Anacor Pharmaceuticals (ANAC)

Trade-Ideas LLC identified Anacor Pharmaceuticals (ANAC) as a new lifetime high candidate

10 Best Biotech Stocks in the NASDAQ

10 Best Biotech Stocks in the NASDAQ

The biotech sector has been one of the fastest growing sectors through June 30, 2015. Here are the 10 best biotech stocks this year.

Anacor Pharmaceuticals Announces Amendment To KERYDIN Commercialization Agreement

Anacor Pharmaceuticals Announces Amendment To KERYDIN Commercialization Agreement

Anacor Pharmaceuticals, Inc. (NASDAQ:ANAC) today announced an amendment to its distribution and commercialization agreement with Sandoz Inc.

Anacor Pharmaceuticals (ANAC) Is Today's Strong On High Volume Stock

Anacor Pharmaceuticals (ANAC) Is Today's Strong On High Volume Stock

Trade-Ideas LLC identified Anacor Pharmaceuticals (ANAC) as a strong on high relative volume candidate

Anacor Pharmaceuticals (ANAC) Hits New Lifetime High

Anacor Pharmaceuticals (ANAC) Hits New Lifetime High

Trade-Ideas LLC identified Anacor Pharmaceuticals (ANAC) as a new lifetime high candidate

Amid Risk, Keep Cash Handy

News is bearish, but that could change quickly.

Where the Money Was Made the Last 5 Years

Where the Money Was Made the Last 5 Years

Only one fund category (of 20) has beaten the S&P 500 over half a decade.

Anacor Pharmaceuticals Names Graeme Bell As New Executive Vice President And Chief Financial Officer

Anacor Pharmaceuticals Names Graeme Bell As New Executive Vice President And Chief Financial Officer

Anacor Pharmaceuticals, Inc. (NASDAQ:ANAC) today announced that Graeme Bell will join Anacor as its new Executive Vice President and Chief Financial Officer.

Today Anacor Pharmaceuticals (ANAC) Hits New Lifetime High

Today Anacor Pharmaceuticals (ANAC) Hits New Lifetime High

Trade-Ideas LLC identified Anacor Pharmaceuticals (ANAC) as a new lifetime high candidate

Anacor Pharmaceuticals To Present At Upcoming Investor Conferences

Anacor Pharmaceuticals To Present At Upcoming Investor Conferences

Anacor Pharmaceuticals, Inc. (NASDAQ:ANAC) announced today that Paul Berns, the company's Chairman, President and Chief Executive Officer, will provide a company overview at the following upcoming investor conferences:...

Short Interest Falls 18.3% For ANAC

Short Interest Falls 18.3% For ANAC

The most recent short interest data has been released by the NASDAQ for the 04/30/2015 settlement date, which shows a 834,285 share decrease in total short interest for Anacor Pharmaceuticals Inc , to 3,716,878, a decrease of 18.33% since 04/15/2015. Total short interest is just one way to look at short data; another metric that we here at Dividend Channel find particularly useful is the "days to cover" metric because it considers both the total shares short and the average daily volume of shares traded.

Anacor Pharmaceuticals Reports First Quarter 2015 Financial Results

Anacor Pharmaceuticals Reports First Quarter 2015 Financial Results

Anacor Pharmaceuticals, Inc. (NASDAQ:ANAC) today announced its financial results for the quarter ended March 31, 2015.

Insider Trading Alert - GM, LOGM And ANAC Traded By Insiders

Insider Trading Alert - GM, LOGM And ANAC Traded By Insiders

Stocks with insider trader activity include GM, LOGM and ANAC

Anacor Pharmaceuticals To Present At Upcoming Investor Conferences

Anacor Pharmaceuticals To Present At Upcoming Investor Conferences

Anacor Pharmaceuticals, Inc. (NASDAQ:ANAC) announced today that Paul Berns, the company's Chairman, President and Chief Executive Officer, will provide a company overview at the following upcoming investor conferences:...

Today's Dead Cat Bounce Stock Is Anacor Pharmaceuticals (ANAC)

Today's Dead Cat Bounce Stock Is Anacor Pharmaceuticals (ANAC)

Trade-Ideas LLC identified Anacor Pharmaceuticals (ANAC) as a "dead cat bounce" (down big yesterday but up big today) candidate

Anacor Pharmaceuticals Announces First Quarter 2015 Financial Results Conference Call And Webcast

Anacor Pharmaceuticals Announces First Quarter 2015 Financial Results Conference Call And Webcast

Anacor Pharmaceuticals, Inc. (NASDAQ:ANAC) will release its financial results for the quarter ended March 31, 2015, after the close of market on Wednesday, May 6, 2015.

First Week of July 17th Options Trading For Anacor Pharmaceuticals

First Week of July 17th Options Trading For Anacor Pharmaceuticals

Investors in Anacor Pharmaceuticals Inc saw new options begin trading this week, for the July 17th expiration. One of the key inputs that goes into the price an option buyer is willing to pay, is the time value, so with 86 days until expiration the newly trading contracts represent a potential opportunity for sellers of puts or calls to achieve a higher premium than would be available for the contracts with a closer expiration.

New Lifetime High Reached: Anacor Pharmaceuticals (ANAC)

New Lifetime High Reached: Anacor Pharmaceuticals (ANAC)

Trade-Ideas LLC identified Anacor Pharmaceuticals (ANAC) as a new lifetime high candidate

Ratings Changes Today

TheStreet Quant Ratings provides fair and objective information to help you make educated investing decisions. We rate over 4,300 stocks daily and provide 5-page PDF reports for each stock. These ratings can change daily and today's changes are reflected in the email below. If you are looking to check-up on the stocks you currently own or are looking for new ideas, you can find our full database of password-protected ratings reports in our proprietary ratings screener: http://www.thestreet.com/k/qr/flat/stock-screener.html Upgrades: ARPI, DWA Downgrades: ANAC, DXPE, EGL, MED Initiations: ARGS Read on to get TheStreet Quant Ratings' detailed report:

Insider Trading Alert - ANAC, ADC And RDNT Traded By Insiders

Insider Trading Alert - ANAC, ADC And RDNT Traded By Insiders

Stocks with insider trader activity include ANAC, ADC and RDNT

Strong On High Relative Volume: Anacor Pharmaceuticals (ANAC)

Strong On High Relative Volume: Anacor Pharmaceuticals (ANAC)

Trade-Ideas LLC identified Anacor Pharmaceuticals (ANAC) as a strong on high relative volume candidate

A Dangerous Complacency

A Dangerous Complacency

Investors' lack of fear is troubling.